曲美他嗪与阿托伐他汀钙治疗冠心病心绞痛伴血脂异常患者的效果研究

目的探讨曲美他嗪与阿托伐他汀钙治疗冠心病心绞痛伴血脂异常患者的效果。方法88例冠心病心绞痛伴血脂异常患者作为研究对象,以随机数字表法分为对照组与研究组,各44例。两组均应用常规扩血管药物、利尿剂、吸氧等对症治疗措施。在此基础上,对照组应用曲美他嗪治疗,研究组应用曲美他嗪联合阿托伐他汀钙治疗。对比两组临床治疗效果、治疗前后血脂指标水平、治疗前后血清炎症因子指标水平以及治疗期间不良反应发生情况。结果研究组治疗总有效率为93.18%,高于对照组的72.73%,差异具有统计学意义(P<0.05)。治疗后,研究组甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)与低密度脂蛋白胆固醇(LDL-C)水平分别为(1.16±0.52)、(3.65±0.52)、(2.00±0.38)mmol/L,均低于对照组的(1.88±0.65)、(4.62±0.50)、(2.70±0.45)mmol/L,HDL-C水平(1.68±0.52)mmol/L高于对照组的(1.28±0.35)mmol/L,差异具有统计学意义(P<0.05)。治疗后,研究组血清肿瘤坏死因子-α(TNF-α)与超敏C反应蛋白(hs-CRP)水平分别为(14.22±3.52)ng/L、(2.40±1.85)mg/L,均低于对照组的(20.58±4.00)ng/L、(6.85±2.98)mg/L,差异具有统计学意义(P<0.05)。研究组治疗期间不良反应发生率为4.55%,与对照组的4.55%对比,差异无统计学意义(P>0.05)。结论曲美他嗪与阿托伐他汀钙治疗冠心病心绞痛伴血脂异常疗效确切,可以有效改善患者的临床症状,调节血脂与炎症因子指标水平,且安全性佳,值得临床推广。

Study on effect of trimetazidine and atorvastatin calcium in coronary heart disease angina pectoris patients with dyslipidemia

Objective To discuss the effect of trimetazidine and atorvastatin calcium in coronary heart disease angina pectoris patients with dyslipidemia.Methods A total of 88 coronary heart disease angina pectoris patients with dyslipidemia as study subjects were divided into control group and research group by random number table method,with 44 cases in each group.Both groups were treated with symptomatic treatments such as conventional vasodilator drugs,diuretics,and oxygen inhalation.On this basis,the control group was treated by trimetazidine,and the research group was treated by trimetazidine and atorvastatin calcium.The clinical therapeutic effect,the level of blood lipid index and serum inflammatory factor index before and after treatment,and occurrence of adverse reactions during treatment were compared between the two groups.Results The total effective rate of treatment of the research group was 93.18%,which was higher than that of the control group 72.73%,and the difference was statistically significant(P<0.05).After treatment,the levels of triglyceride(TG),total cholesterol(TC),high density lipoprotein cholesterol(HDL-C)and low density lipoprotein cholesterol(LDL-C)of the research group were(1.16±0.52),(3.65±0.52)and(2.00±0.38)mmol/L,which were all lower than those of the control group(1.88±0.65),(4.62±0.50)and(2.70±0.45)mmol/L,and HDL-C(1.68±0.52)mmol/L was higher than that of the control group(1.28±0.35)mmol/L.The difference was statistically significant(P<0.05).After treatment,the levels of serum tumor necrosis factor-α(TNF-α)and high-sensitivity C-reactive protein(hs-CRP)of the research group were(14.22±3.52)ng/L and(2.40±1.85)mg/L,which were lower than those of the control group(20.58±4.00)ng/L and(6.85±2.98)mg/L,and the difference was statistically significant(P<0.05).The incidence of adverse reactions during treatment of the research group was 4.55%,which had no statistically significant difference compared with that of the control group 4.55%(P>0.05).Conclusion Trimetazidine and atorvastatin calcium shows affirmative efficacy in coronary heart disease angina pectoris patients with dyslipidemia,which can effectively improve the clinical symptoms of patients,regulate blood lipid and inflammatory factor levels with high safety.It is worthy of clinical promotion.